Introduction
Evidence-based clinical practice guidelines recommend vitamin K antagonists in the prevention of stroke in atrial fibrillation 1, 2 , in coumarin derivatives, including warfarin and acenocoumarol, and indanedione derivatives, including fluindione and phenindione.
Fluindione constitutes about 80 of AVK prescriptions in France 8 .
AVK are characterised by a large between-, but also within-patient variability in the dose-response relationship. The therapeutic window is narrow, so that clinicians must walk a thin line between suboptimal dosage risking thromboembolic events and higher doses potentially risking bleeding episodes. The frequency and seriousness of haemorragic adverse events varies in the literature, depending on the population, the prescribed therapeutic range, the other treatments co-administered and the duration of treatment with AVK 9 .
The [ ] Adverse Event Reporting system of the US Food and Drug Administration provides evidence that warfarin is among the top 10 drugs with the greatest number of serious adverse events. In France, where the present study was performed, iatrogenic events due to oral anticoagulant drugs represent the first cause of hospital admission for drug-related adverse event 10 , totalling about 17000 admissions a [ ] year, and an estimated 3000 to 5000 deaths 11 . A meta-analysis of available clinical trials in patients anticoagulated for venous [ ] thromboembolism, reported a case-fatality rate of major bleeding of 13.4 in all patients (95 confidence interval 9.4 to 17.4 ) 12 .
Haemorragic events are overall more frequent and more severe in elderly patients compared to the general population 13 . The [ ] contribution of age to this increased risk is somewhat controversial, some studies pointing to an increase of the incidence of per se haemorragic events as a function of age 9 while others do not find it significant 14 , but the fact that severity increases with age is large part of this variability can be explained by changes in the dose-concentration relationship (pharmacokinetics, PK), or in the concentration-response relationship (pharmacodynamics, PD). Measurement of AVK concentrations can contribute to a better understanding of these two components by separating these two contributions.
In the present paper, we describe the findings from the PREPA study, investigating the pharmacokinetics and pharmacodynamics of fluindione in octogenarians using non-linear mixed effect models. The primary objective of PREPA was to study the factors influencing the source of variability in the response to fluindione in elderly inpatients starting fluindione, with a special interest in comorbidities and comedications.
Results

Data
151 subjects were recruited in PREPA, 131 of whom provided PK/PD data and were included in the present PK/PD analysis. Table 1 shows the demographic and biologic variables recorded in this population.
The prescribed therapeutic range for INR was 2 3 for all the patients included in the study. The elderly patients included in the [ -] PREPA study were generally polymedicated: on the first day of the study, they received on average 8 different medications in addition to fluindione. In this study, initial dosing of fluindione was conservative: the initial dose was 5, 10 and 15 20 mg in 28, 94 and 10 subjects -respectively. The median duration of stay in the study was 8 days (range 2 to 31 days). The last dose of fluindione was 5 mg or less for 32 subjects, 7.5 10 mg for 54 patients, 12. INR between 2 and 3.
Ten subjects (8 ) experienced bleeding during the study, as described elsewhere 20 . Nine of these patients also received heparin
prior to initiating fluindione treatment, and severe bleeding occurred in 5 of them, always associated with the heparin treatment. The tenth subject, who suffered from hemorroids and constipation, started heparin on day 2 and experienced minor bleeding the next day, which resolved quickly.
Base model building
The PK dataset included 493 concentrations of fluindione, and the PD dataset 477 measurements of INR. A one-compartment model without lag-time provided an adequate fit to the PK data, based on tests and diagnostic graphs. Although the estimation error for the absorption rate constant k was reported as reasonable, its interindividual variability (IIV) was large, and this parameter proved relatively a unstable from run to run, especially at later stages when covariates were included in the model. Because there was little information about the absorption phase, we considered a model where k was fixed without variability. In a study in healthy volunteers, fluindione was found a to be quickly absorbed, with an average T of 2.0 h (range 0.5 6.0 h) 21 , while the elimination half-life was 35 h (SD 6.5 h An indirect response model for 1/INR was found adequate in the PK/PD analysis. INR values increase from baseline value of 1 in a normal patient, and the estimate of the additive part of the combined error model converged to a very small value. Therefore the residual variability for the INR model was modelled as proportional. A diagonal covariance matrix was used to model IIV. The Hill coefficient was significantly different from 1, and assuming a linear model instead of the I model also degraded the fit. Models including precursors max were also tested to account for time delays but did not improve the fit or the likelihood.
Covariate model building
Covariates were first included on V and CL. Using the individual parameters estimates from the base model, the following covariates were found to have an influence on V, CL or both, and were considered for inclusion in the model: gender, weight, age, surgery, atrial fibrillation, renal function, Mini-Mental State (MMS) score, as well as administration of cordarone and deroxat. After pruning down the model, the following relationships remained: the volume of distribution V was found to increase with weight, and to be higher in men;
clearance CL on the other hand was found to decrease with age, and to be lower in patients who received cordarone during the study. We also explored the relationships between parameters and time-varying comedications by considering each occasion as a separate subject.
None of these comedications was found to influence the two PK parameters.
For the PD parameters, the following candidate relationships were found: CLCR, nonagerian, surgery and protamine on I , deroxat on 0 I , CLCR, surgery and protamine on k , nonagerian, surgery and protamine on C , Activities of Daily Living (ADL) score, surgery max out 50
and deroxat on . In the final model, patients recovering from cardiac surgery were found to have reduced C and , translating to higher
sensitivity. These patients were younger but age did not remain in the model. Deroxat increased .
γ
The variability on I was poorly estimated and was removed from the final model. In most models we found I to be very close to 1, max 0 but the assumption I 1 led to a significant increase in the statistical criterion. 0 = We performed a small stability study to assess the ability of the sparse design to estimate the PK parameters, and found that CL and V drawn to show the doses received (the scale for doses is on the right-hand axis). For most subjects, the model is able to reproduce both PK and PD measurements adequately, describing even complex profiles. In a few cases, (eg subject 1086, topmost panel, right), the PK is very well predicted but the PD shows unexplained fluctuations, with INR starting to decrease despite stable doses and concentrations.
Final model
Using the steady-state approximation with the population parameters, we found that doses of 7.5 and 10 mg ensure an INR within the therapeutic range for a typical patient (weight 65 kg, age 85 kg), regardless of gender. IIV however is large, and often at least 2 doses provide an INR within the range. Table 3 shows dose recommendations depending on individual covariates, obtained by simulations under the model. In each setting, when taking into account IIV, this average dose is valid in about 20 of the simulations, while a dose within / % + 2.5 mg of this dose is recommended in about 50 of the simulations. demonstrated not only large IIV, but also, through a follow-up study recording dose changes and evolution of anticoagulation after discharge from the hospital, a sizeable intraindividual variability. This variability led to fluctuations in the anticoagulation level even in patients thought to be stabilised when leaving the hospital 27 .
[ ]
In the present study, we used a PK/PD model closely related to the one developed in ADAP. The main differences are the absorption model, which was previously assumed to a bolus dose and which we fixed here, and the use of a Hill model to represent drug effect. The estimates of CL and V were very close to the value estimated assuming an IV bolus, but the statistical criterion was slightly better with an oral absorption phase. The estimates of the PK parameters however are quite different from previously 25, 26 . In the final model, V was [ ] estimated to be around 8 L, while CL was 0.1 L.hr . In the ADAP study on the other hand, we estimated these parameters to be initially or less. Thus, compared to the previous study, we observe a marked increase in the exposure to fluindione. Since fluindione is administered orally, the reported V and CL are apparent parameters, so an explanation to this discrepancy with previous results is a difference in bioavailability between the two studies. However, this would require a more than four-fold increase in bioavailability in elderly patients compared to the younger population previously studied. Fluindione is to some extent cleared by the liver, with the hepatic metabolism of fluindione appearing to be mediated by CYP2C9 28 , but is mainly renally excreted, so that we do not expect first-pass We used the model and parameter estimates to predict a dose that should be given in order to maintain an INR within the therapeutic range at steady-state. Consistent with the observation that the concentrations were higher in this population of elderly patients than in the population we previously studied 25, 26 , the model predicted relatively low doses, suggesting a daily 10 mg dose, or an alternance of 5
and 10 mg doses, should be a safe starting dose for most patients. This is also in line with the maintenance doses observed in the retrospective study by Mah 31 . Fluindione however is still packaged as 20 mg pills, which are in practice difficult to divide for routine
The present study was targeted towards elderly patients during hospitalisation, since this population is both more likely to receive anticoagulant drugs and more fragile, being often polymedicated and with comorbidities. These patients are therefore more susceptible to bleeding and dose adjustment for oral anticoagulants is particularly difficult 32 . Given its observational nature and the short duration, the [ ] PREPA study was not specifically designed to investigate risk factors for clotting or bleeding; a more detailed analysis of the 8 bleeding events which occurred in the subset of patients with atrial fibrillation can be found in 20 . A major objective of the present study was to [ ] identify covariates that could explain some of the variability in the response. We found the pharmacokinetic parameters to be influenced by gender, weight and age, as well as prior administration of cordarone (amiodarone) while the only covariates influencing pharmacodynamic parameters were prior surgery and administration of deroxat. We did not find any relationship with time-varying comedications, but this may be due to the heterogeneity of the population and to the small sample size. Cordarone has been reported to increase the haemorragic risk 33 , which could relate to the 20 reduction we find, translating into an increased exposure. We did not find
a relationship with anti-infective agents (antibiotics and anti-fungal drugs) as in that study; nearly half of the patients received an antibiotic at some point during treatment, but it is possible that the analysis could not pick up a relationship especially if the influence is delayed, since we considered only an on/off type of relationship. Also the sample size was too small to consider each drug separately so we pooled the different antibiotics and the different dosages for the analyses. About a third of the patients took part in the optional pharmacogenetic study. We found no relationship between the 3 genetic polymorphisms and PK or PD parameters. The influence of CYP2C9 on PK through metabolism has been described for warfarin 34 ; for fluindione, a recent study in healthy volunteers showed a lower clearance in [ ] carriers of the 3 allele 28 , while the influence on the response is expected to be related to VKORC1 35, 28 . We were not able to
confirm these relationships here, perhaps due to the small number of subjects.
Most patients did not remain in the study long enough to reach a stable INR. However, even within the duration of their stay, we noted that dose changes occurred too often and sometimes irrationally. In particular, the long time-course of INR evolution after AVK did not appear well anticipated by the prescribing clinicians. This is apparently partly due to a lack of follow-up, as doses are frequently modified [ ]
In conclusion, the PREPA observational study highlighted that dose adjustement for AVK agents is still a major issue, especially in the elderly. The complexity of INR dynamics and the resulting delay between the time-course of the drug and the clinical variations of anticoagulation levels make it difficult to anticipate changes in INR, so that adjustements in doses must be made after taking into account the evolution over several days and not a single measurement. Elderly patients should be treated as a special population presenting a noticeably increased pharmacokinetic exposure to the drug. They should receive significantly lower doses and the onset of treatment should remain conservative.
Methods
Data
The PREPA study was a prospective, observational multicenter study conducted between For each patient, the following variables were recorded at the inclusion visit by a clinician involved in the study: age, gender, weight, weight changes within the 6 months preceding the inclusion visit, ADL, Charlson comorbidity score, MMS, reason for fluindione treatment, therapeutic range for INR, major comorbidities, cardiac surgery. A number of biological variables were also measured at baseline: albumin, C-reactive protein (CRP), haematocrit levels, protidaemia, natremia. Creatinine clearance (CRCL) was computed from age (year) and creatinine clearance using the following formula 41 :
Renal function was classified as normal (CLCR 60 ml/mn), moderately impaired (CLCR between 30 60 ml/mn) and severely ≥ -impaired (CLCR<30 ml/mn).
Patients were defined as suffering from malnutrition when they had recent severe weight loss (over 10 of weight), a body mass index % lower than 18, or albumin levels lower than 30. Finally, high levels of CRP (CRP>50 mg.L ) were considered to be a sign of current 1 − hypercatabolism.
One important objective in this group of elderly inpatients was to describe and take into account the many comedications these patients received. Comedications given to each patient were recorded at the initial visit, and changes were documented throughout the study.
Comedications received were classified according to their influence on INR, using the classification proposed by Holbrook 42 (given in [ ] Supplementary Table S2 ). Drugs were first classified according to whether they increase the thrombotic risk or the haemorragic risk; the second group was divided further into drugs increasing the INR (class B2) versus drugs acting independently (class B1). Nonsteroidal anti-inflammatory drugs (group B12) and diuretics were also considered for their potential effect on pharmacokinetic parameters. For each class and each subject, we defined a daily indicator variable. Cordarone, amiodarone and deroxat, because of their long half-life, were considered separately and assumed to remain active for 1 month (cordarone and amiodarone) and 15 days (deroxat). Only therapeutic classes which were received by at least 10 and at most 122 patients were considered in the analysis.
Model building
Non-linear mixed effect models were used in this analysis; the th observation in subject , , is modelled as: j i y ij (2) where denotes the individual parameters, the structural model and the residual error model ( ~ (0, 1)). We assume that 
Base model selection
We first studied the PK of fluindione alone. The residual variability was modelled using a combined error model. The structural model was built by selecting the best model amongst one and two-compartmental models with first or zero-order absorption, with or without lag-time.
The evolution of INR was modelled using a turnover model, describing the evolution of coagulation factor activity ( ) 1 ( ) F t = /INR t through the following equation:
The model was parameterised in terms of and INR 1 where, in the absence of drug, we have the relationship:
I was assumed to follow a logit distribution while all the other parameters had a log-normal distribution.
For each parameter we max tested whether IIV could be removed from the model, and we also tested correlations between parameters by introducing covariances. To 7 16 select structural and variability models, we used appropriate likelihood ratio tests (LRT), based on the log-likelihood computed using importance sampling.
Covariate model building
We examined the relationships between parameters and covariates, first in the PK model alone, then in the PK/PD model. Covariate model building was done by exploring the relationships between covariates and estimated individual parameters (obtained as the conditional modes of the individual distribution) through linear regression for the continuous covariates and parametric tests for the categorical covariates; all candidate covariates were included in a full model, using power functions for continuous covariates; the model was then pruned down by removing covariate effects for which the p-value of the Wald test was larger than 0.05, starting with the covariates which had the largest p-value. A non-significant Wald test indicates a high estimation error for the corresponding parameter.
The same approach was used for the full PK/PD model with the best PK model, re-estimating all parameters. The final PK/PD model was evaluated using standard diagnostic graphs provided by MONOLIX. We also computed the shrinkage, as, for the th-parameter: k
where is the estimated th random effect in subject . The -shrinkage was computed separately for PK and PD:
where IWRES denotes the individual weighted residuals. In the presence of high shrinkage, diagnostic plots based on individual estimated parameters are less informative 45 .
Covariates missing in more than 14 subjects (10 ) were excluded from the analysis; the other missing covariates were imputed to the % mean value for continuous variables and to a value randomly sampled for the discrete covariates. The final model was checked using multiple imputation 46 , using the package mice for R 47 . An additional exploratory analysis investigated relationships between the
PK/PD parameters and the genetic covariates in subsets of the data.
Steady-state dose
Fluindione is provided as 20 mg tablets, which can be cut in four 5 mg pieces; dosage is often alternated (eg 10 mg one day and 5 the next 
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Figure 2
Goodness-of-fit plots: (top) observed versus predicted fluindione concentrations; (bottom) observed versus predicted INR. The plots on the left were obtained with population parameter estimates, while the plots on the right were obtained with individual parameter estimates. The solid line represents the unity line around which points are expected to scatter evenly.
Figure 3
Goodness-of-fit plots: npde with prediction intervals, for fluindione (left) and INR (right) versus time (top) and predictions (bottom). The blue areas correspond to the prediction intervals for the median (central band) and for the limits of the 95 prediction interval; the thin dotted lines % represent the predictions of the median and the limits, while the thick red lines show the corresponding observed values.
Figure 4
Individual fits for 12 subjects, fluindione concentrations. Patient numbers starting with 1 indicate patients recruited in the cardiology department, with 3 or 4 one of the two geriatric departements, and with 5 the internal medicine department.
Figure 5
Individual fits for the same subjects, INR, superimposed with the daily dosing pattern as vertical bars (scale for doses are on the right-hand axis). The following parameter-covariate relationships were estimated, with denoting the individual: i (7) where for instance Men is 1 if is a man and 0 if a woman. Weight was centered on 60 kg, while age was centered on 90 yr. i
